Heatmap Highlights: Tech rotation, defensive surge shape S&P 500
Seeking Alpha News (Fri, 26-Jun 4:39 PM ET)
Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
Seeking Alpha News (Fri, 26-Jun 12:22 PM ET)
Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms
Seeking Alpha News (Fri, 26-Jun 12:22 PM ET)
TipRanks (Fri, 26-Jun 11:55 AM ET)
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
PRNewswire (Fri, 26-Jun 8:00 AM ET)
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Ionis Pharmaceuticals (IONS)
TipRanks (Fri, 26-Jun 4:41 AM ET)
Heatmap Highlights: Divergence in S&P 500 as mega-caps bleed while semis surge
Seeking Alpha News (Thu, 25-Jun 4:36 PM ET)
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha News (Thu, 25-Jun 1:59 PM ET)
Globe Newswire (Thu, 25-Jun 9:04 AM ET)
RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)
TipRanks (Wed, 24-Jun 9:45 PM ET)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Abbvie trades on the NYSE stock market under the symbol ABBV.
As of June 26, 2026, ABBV stock price climbed to $253.35 with 27,805,324 million shares trading.
ABBV has a beta of -0.19, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.01 to the broad based SPY ETF.
ABBV has a market cap of $448.12 billion. This is considered a Mega Cap stock.
Last quarter Abbvie reported $15 billion in Revenue and $2.65 earnings per share. This beat revenue expectation by $272 million and missed earnings estimates by -$.01.
In the last 3 years, ABBV traded as high as $253.35 and as low as $130.96.
The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABBV has outperformed the market in the last year with a price return of +40.3% while the SPY ETF gained +21.3%. ABBV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.1% and +12.7%, respectively, while the SPY returned +11.3% and -0.9%, respectively.
ABBV support price is $238.67 and resistance is $247.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.